Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Monika Benner

Nurse Practitioner Mokena, IL Nurse Practitioner

NPI 1871081711 CMS profile 10753081

19060 Everett Blvd Ste 112, Mokena, IL 60448

Open in the dashboard

General payments

$14,175

638 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monika Benner of Mokena, IL is reported in the CMS Open Payments database as having received $14,175 across 638 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,347 136
2024 General $2,930 102
2023 General $2,703 152
2022 General $2,302 108
2021 General $2,893 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monika Benner
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Monika Benner were reported at $3,347. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Monika Benner Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,893 $135 $40–$426 $132
2022 $2,302 $152 $48–$470 $149
2023 $2,703 $166 $54–$529 $160
2024 $2,930 $173 $55–$556 $164
2025 $3,347 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $2,545 95 payments
  2. AstraZeneca Pharmaceuticals LP $1,886 74 payments
  3. Lilly USA, LLC $684 24 payments
  4. Merck Sharp & Dohme Corporation $575 32 payments
  5. Pfizer Inc. $529 31 payments
  6. Janssen Biotech, Inc. $488 25 payments
  7. AbbVie, Inc. $483 21 payments
  8. Astellas Pharma US Inc $460 24 payments
  9. Incyte Corporation $445 20 payments
  10. Daiichi Sankyo Inc. $439 23 payments
  11. Other $5,640 269 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,468 608 payments
  2. Education $1,527 18 payments
  3. Long term medical supply or device loan $1,180 12 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,799 48 payments
  2. CALQUENCE $642 24 payments
  3. LYNPARZA $563 19 payments
  4. VERZENIO $526 19 payments
  5. KEYTRUDA $508 29 payments
  6. LIBTAYO $410 32 payments
  7. VENCLEXTA $396 16 payments
  8. IMBRUVICA $353 19 payments
  9. RETEVMO $343 11 payments
  10. ENHERTU $312 13 payments
  11. Other $10,189 512 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

405

Median for Nurse Practitioner: 389

Drug cost

$312,131

Median for Nurse Practitioner: $21,885

Branded share of claims

28.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Verzenio Abemaciclib Brand 18 $259,646
Eliquis Apixaban Brand 64 $48,563
Letrozole Generic 48 $888
Anastrozole Generic 43 $633
Dexamethasone Generic 59 $611
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $516
Duloxetine Hcl Generic 27 $361
Hydrocortisone Generic 12 $230
Prochlorperazine Maleate Generic 14 $160
Ondansetron Hcl Generic 17 $123

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 58 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
$1,009 — —
VENCLEXTA
$152 — —
RYBREVANT
$117 — —
Padcev
$107 — —
ENHERTU
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 58 with Patron

Records

638 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record